Sort   by:  
 Page size 
UnknownCombining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.
Not available
S-EPMC4164812 | biostudies-literature
UnknownSouthwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
Not available
S-EPMC4226807 | biostudies-literature
UnknownPhase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
Not available
S-EPMC4878037 | biostudies-literature
UnknownEvaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
Not available
S-EPMC5070547 | biostudies-literature
UnknownIncidence of cystoid macular edema after Descemet's stripping automated endothelial keratoplasty.
Not available
S-EPMC5514269 | biostudies-literature
UnknownPhase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Not available
S-EPMC4878048 | biostudies-literature
GenomicHigh Response Rate to Anti PD-1 Therapy in Desmoplastic Melanoma

Desmoplastic melanoma (DM) is a rare subtype of melanoma characterized by dense fibrous stroma, resistance to chemotherapy and a lack of actionable driver mutations, but is highly associated with ultraviolet light DNA damage. We analysed 60 patients with advanced DM treated with programmed cell d...

phs001469 | dbGaP
UnknownProgrammed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Not available
S-EPMC5562434 | biostudies-literature
TranscriptomicsGene expression profiling of melanoma cell lines by high throughput sequencing
A panel of 29 melanoma cell lines were gene expression profiled by RNA-Seq. mRNA profiles of 29 melanoma cell lines
ORGANISM(S): Homo sapiens 
2014-12-16 | E-GEOD-62526 | biostudies-arrayexpress
ProteomicsProteomics of Mouse Syngeneic Models
The cell line-derived xenografts and patient derived xenografts have limited use in cancer immunotherapy evaluation because an immune compromised host is required for xenotransplantation. Syngeneic mouse models are derived by transplanting established mouse cell lines or tumor tissues to strain matc...
ORGANISM(S): Mus musculus (Mouse) 
2019-12-03 | PXD011885 | Pride
Mouse sygeneic Immuno-oncology Tumor 
Sort   by:  
 Page size